Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

45¼¼ ÀÌÇÏÀÇ À¯¹æ¾ÏȯÀÚ¿¡¼­ Á¶Á÷¹Ì¼¼¹è¿­¹ýÀ» ÀÌ¿ëÇÑ ¸é¿ªÁ¶Á÷È­ÇÐÀû »ýüǥÁöÀÚÀÇ ¿ªÇÒ The Role of Immunohistochemical Biomarkers as Prognostic Factors by the Use of a Tissue Microarray in Breast Cancer Patients Under 45-years-old

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2008³â 26±Ç 1È£ p.45 ~ 55
±èÀº¼®, Áø¼Ò¿µ, À̵¿È­, À̱ÔÅÃ, ¿øÁ¾È£, ¹ÚÈñ¼÷, ±è¼º¿ë, À̹ÎÇõ, ÃÖµÎÈ£, ±è¿ëÈ£,
¼Ò¼Ó »ó¼¼Á¤º¸
±èÀº¼® ( Kim Eun-Seog ) 
¼øõÇâ´ëÇб³ ¹æ»ç¼±Á¾¾çÇб³½Ç

Áø¼Ò¿µ ( Jin So-Young ) 
¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
À̵¿È­ ( Lee Dong-Wha ) 
¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
À̱ÔÅà( Lee Kyu-Taek ) 
¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¿øÁ¾È£ ( Won Jong-Ho ) 
¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹ÚÈñ¼÷ ( Park Hee-Sook ) 
¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è¼º¿ë ( Kim Sung-Yong ) 
¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
À̹ÎÇõ ( Lee Min-Hyuk ) 
¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
ÃÖµÎÈ£ ( Choi Doo-Ho ) 
¼øõÇâ´ëÇб³ ¹æ»ç¼±Á¾¾çÇб³½Ç
±è¿ëÈ£ ( Kim Yong-Ho ) 
¼øõÇâ´ëÇб³ ¹æ»ç¼±Á¾¾çÇб³½Ç

Abstract

¸ñÀû: 45¼¼ ÀÌÇÏÀÇ À¯¹æ¾Ï ȯÀÚÀÇ Á¾¾çÁ¶Á÷ÀÇ ÆĶóÇÉ ºí·ÏÀ» Á¶Á÷¹Ì¼¼¹è¿­¹ý(Tissue Microarray, TMA)À¸·Î ¸¸µé¾î ¿¡½ºÆ®·Î°Õ ¼ö¿ëü(ER), ÇÁ·Î°Ô½ºÅ×·Ð ¼ö¿ëü(PR), HER-2, COX-2 ¹× Survivin µî 5°¡ÁöÀÇ »ýüǥÁöÀÚÀÇ ¹ßÇö»óÅÂ¿Í »óÈ£°ü°è, ȯÀÚÀÇ Ä¡·á ÈÄ ÃßÀû°üÂû »óÅÂ¿Í °ü·Ã¼ºÀ» ºÐ¼®ÇÏ¿© ¿¹ÈÄÀÎÀڷμ­ÀÇ ÀÇÀǸ¦ ¿¬±¸ÇÏ´Â µ¥ ÀÖ´Ù.

´ë»ó ¹× ¹æ¹ý: 1994³â 3¿ùºÎÅÍ 2005³â 8¿ù±îÁö ¼ö¼úÀ» ½ÃÇàÇÑ 45¼¼ ÀÌÇÏÀÇ À¯¹æ¾Ï ȯÀÚ Áß¿¡¼­ TMA ºÐ¼®ÀÌ °¡´ÉÇÑ 212¸íÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÇÏ¿´´Ù. ȯÀÚÀÇ ³ªÀÌ´Â 23¼¼ºÎÅÍ 45¼¼±îÁö·Î Áß¾Ó ³ªÀÌ°¡ 39¼¼À̾úÀ¸¸ç ÃÖ¼Ò ÃßÀû°üÂû±â°£Àº 24°³¿ù, Áß¾Ó ÃßÀû °üÂû±â°£Àº 60°³¿ùÀ̾ú´Ù. 45¼¼ ÀÌÇÏÀÇ È¯ÀÚ¸¦ ¼±ÅÃÇÑ ÈÄ ¼ö¼ú Á¶Á÷Ç¥º»À» ã¾Æ HE¿°»öµÈ ½½¶óÀ̵带 ÅëÇØ ¾Ï ºÎÀ§¸¦ Ç¥½ÃÇÑ ÈÄ TMA Àåºñ¸¦ ÅëÇØ ¹Ì¼¼Á¶Á÷¹è¿­À» ¸¸µé¾ú´Ù. ±×¸®°í ´Ù¼¸ °¡Áö »ýüǥÁöÀÚ¿¡ ´ëÇÑ ¸é¿ªÁ¶Á÷È­ÇÐ ¿°»öÀ» ½ÃÇàÇÏ¿´À¸¸ç º´¸®Àü¹®ÀÇ°¡ Æǵ¶ÇÏ¿´´Ù. ±×¸®°í ÀÌ °á°ú¿Í ȯÀÚµéÀÇ ¿¬·É, º´±â, ¸²ÇÁÀý ÀüÀÌ, ¼ö¼ú¹æ¹ý, ´Ù¾çÇÑ ¾à¹°¿ä¹ý°ú °¡Á··Â µî ¿©·¯ °¡Áö ÀÎÀÚ¿Í È¯ÀÚÀÇ ÃßÀû °üÂû °á°ú¸¦ ÀÔ·ÂÇÏ¿© ¿¹ÈÄÀÎÀÚµéÀ» ºÐ¼®ÇÏ¿´´Ù.

°á°ú: T º´±â¿¡ µû¸¥ ȯÀÚ ºÐÆ÷´Â T1ÀÌ 90¸í, T2°¡ 101¸íÀ¸·Î ´Ù¼ö¸¦ Â÷ÁöÇÏ¿´°í 105¸í(49.5%)¿¡¼­ ¾×¿Í ¸²ÇÁÀýÀÇ ÀüÀÌ°¡ ÀÖ¾ú´Ù. ¸ðµç ȯÀÚÀÇ 5³â ¹«º´ »ýÁ¸À²°ú 5³â »ýÁ¸À²Àº °¢°¢ 82.3%, 90.4%À̾úÀ¸¸ç 36¸íÀÇ È¯ÀÚ°¡ ±¹¼Ò Àç¹ßÀ̳ª ¿ø°ÝÀüÀÌ°¡ ÃßÀû °üÂû±â°£¿¡ ¹ß»ýÇÏ¿´°í 20¸íÀº ¾Ï°ú °ü·ÃÇÏ¿© »ç¸ÁÇÏ¿´´Ù. ER, PR, HER-2, COX-2, ±×¸®°í survivinÀÇ ¾ç¼º ¹ßÇöºñÀ²Àº °¢°¢ 38.2%, 45.3%, 25.9%, 41.5%¿Í 43.4%À̾úÀ¸¸ç Á¾¾çÀÇ Å©±â, ³ªÀÌ, ¸²ÇÁÀýÀüÀÌÀÇ ¿©ºÎ, È£¸£¸ó ¼ö¿ëüÀÇ »óÅÂ, ±×¸®°í HER-2ÀÇ »óÅ°¡ ¹«º´ »ýÁ¸±â°£¿¡ ´ëÇÑ ´Üº¯·® ºÐ¼®»ó Áß¿äÇÑ ¿¹ÈÄÀÎÀÚ À̾úÀ¸¸ç »ýÁ¸À²¿¡ ¹ÌÄ¡´Â ¿µÇâÀº Á¾¾çÀÇ Å©±â, ¸²ÇÁÀýÀÇ ÀüÀÌ, È£¸£¸ó ¼ö¿ëü, ±×¸®°í HER-2ÀÇ ¹ßÇöÀ̾ú´Ù.COX-2³ª survivinÀº ¿¹ÈÄÀÎÀڷμ­ÀÇ ¿ªÇÒÀ» ãÀ» ¼ö ¾ø¾úÀ¸³ª HER-2¿Í COX-2°¡ µ¿½Ã¿¡ ¹ßÇöµÇ´Â °æ¿ì¿¡ ¿¹ÈÄ°¡ ³ª»Û °æÇâÀ» °üÂûÇÒ ¼ö ÀÖ¾ú´Ù. ´Ùº¯·® ºÐ¼®»ó ¿ÀÁ÷ T-º´±â¿Í ¸²ÇÁÀýÀÇ ÀüÀÌ ¿©ºÎ¸¸ÀÌ Áß¿äÇÑ ¿¹ÈÄ ÀÎÀÚÀ̾ú°í ERÀº °æ°èÀÇ Àǹ̰¡ ÀÖ¾ú´Ù.

°á·Ð: 45¼¼ ÀÌÇÏÀÇ ¿©¼º À¯¹æ¾Ï ȯÀÚ¿¡¼­ È£¸£¸ó ¼ö¿ëü »óÅÂ¿Í HER-2´Â ¿¹ÈÄÀÎÀÚÀ̾ú°í COX-2¿Í survivinÀº ¿¹ÈÄÀÎÀڷμ­ÀÇ ¿ªÇÒÀ» ãÀ» ¼ö ¾ø¾ú´Ù.

Purpose: This study evaluates the association of estrogen receptor (ER), progesterone receptor (PR), Her-2, COX-2, and survivin with the clinicopathological features and outcomes in young Korean women with breast cancer using recently developed tissue microarray (TMA) technology.

Materials and Methods: A cohort of 212 young patients with breast cancer diagnosed at the age of 45 years or younger from March 1994 to August 2005, were enrolled in this study. The age range of patients was 23¡­45 years (median age, 39 years). The minimum and median follow-up periods were 24 months and 60 months, respectively. Serial sections of primary tumors were processed by the use of a TMA for immunohistochemical staining for five biomarkers. The correlation of these five biomarkers and the clinicopathological features and outcomes were analyzed by statistical methods.

Results: The majority of the patients were stage T1 (90 patients) or T2 (101 patients), and 105 patients (49.5%) had an axillary node metastasis. The 5-year overall and relapse free survival rates for all of the patients were 90.4% and 82.3%, respectively, and 36 patients had a locoregional or distant metastasis as a first event. Positive expression of ER, PR, Her-2, COX-2, and survivin was determined in 38.2%, 45.3%, 25.9%, 41.5%, and 43.4%, of the tumor samples, respectively. Tumor stage, nodal status, age, as well as expression of ER, PR, and HER-2 status were significantly associated with the disease free survival rate. Tumor stage, nodal status, as well as expression of ER, PR, and HER-2 were significantly related with the overall survival rate. Expression of COX-2 and survivin were not single independent prognostic factors for the disease free and overall survival rate although co-expression of HER-2 and COX-2 had a tendency as a poor prognostic factor. By multivariate analysis, only T stage and lymph node status were significant prognostic factors, and ER status was a marginally significant prognostic factor (p=0.075).

Conclusion: Expression of ER, PR and HER-2 were significant prognostic factors for the relapse free and overall survival rate. Expression of COX-2 and survivin were not prognostic factors for young women with breast cancer.

Å°¿öµå

À¯¹æ¾Ï;Á¶Á÷¹Ì¼¼¹è¿­¹ý;»ýüǥÁöÀÚ
Breastcancer;Tissuemicroarray;Biomarkers

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS